ARCT Stock Analysis: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$5.76
-0.16 (-2.70%)
▼
5d:
+4.16%
30d:
-16.4%
90d:
-33.18%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $5.76, which is considered oversold relative to its 30-day fair value range of $5.84 to $7.05.
Technical Outlook: Technically, ARCT is in a downtrend. Immediate support is located at $5.50, while resistance sits at $6.14.
Market Sentiment: ARCT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $20.60 (+257.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARCT is in a downtrend. Immediate support is located at $5.50, while resistance sits at $6.14.
Market Sentiment: ARCT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $20.60 (+257.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.84 -
$7.05
Company Quality Score
48/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 257.6% below Wall St target ($20.60)
Trading Range Analysis
30-Day Trading Range
$5.84 -
$7.05
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.20
(20.9%)
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$6.14
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.43
Wall Street Target
$20.60
(+257.6%)
Revenue Growth (YoY)
-93.0%
Profit Margin
-143.8%
Share & Embed Analysis
Last updated: August 03, 2026 1:34 AM ET
Data refreshes hourly during market hours. Next update: 2:34 AM
Data refreshes hourly during market hours. Next update: 2:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |
